RAS Amplification as a Negative Predictor of Benefit From Anti-EGFR–Containing Therapy Regimens in Metastatic Colorectal Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Oncologist
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
RAS Amplification as a Negative Predictor of Benefit From Anti-EGFR Containing Therapy Regimens in Metastatic Colorectal Cancer
Oncologist 2021 Jan 19;[EPub Ahead of Print], AB Schrock, JK Lee, J Sandhu, R Madison, C Cho-Phan, JW Snider, E Castellanos, JM Venstrom, M FakihFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.